Classification based on drug efficacy (American Academy of Neurology AAN, International Movement Disorders Society (MDS) can be classified as mildly efficacious, moderately efficacious, and potent drugs. 1. Mild efficacy includes: MAO-B inhibitors: Silegiline or Resagiline: benefit often occurs 1 week after the start of treatment, but it is recommended to start with a small dose and take the last dose before 4-5 pm to avoid inducing insomnia. Amantadine: watch for side effects: insomnia or hallucinations; renal metabolism, renal insufficiency needs to be monitored. Anticholinergic drugs: Antan, effective in tremor, but results are inconsistent (some patients with tremor have poor results) and side effects are significant and need to be closely monitored, not at the cost of cognitive impairment. 2, moderate efficacy: dopaminergic receptor agonists can directly stimulate dopamine receptor sites, including ergot and non-ergot, non-ergot is superior to ergot, as the first choice recommended (Senfuro, Tysudar, ropinirole, etc.). 3, strong: levodopa agents: the gold standard treatment for PD, for early Parkinson’s disease patients, levodopa therapy is not recommended as the first choice, receptor agonists can be preferred (such as Senfro).